TGTX
TG Therapeutics Inc
56.00$
-3.6%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 98.2% | 76.6% | 92.8% | 95.8% | 94.5% | 91.5% | 97.8% | 87.2% | 86.9% | 96.5% | 98.0% | 59.3% | |
| 64.2% | 48.5% | 45.7% | 58.2% | 50.2% | 69.1% | 88.5% | 78.7% | 52.9% | 28.2% | 31.1% | 7.4% | |
| 90.9% | 90.3% | 82.1% | 87.1% | 82.3% | 86.1% | 96.8% | 82.9% | 83.5% | 66.0% | 53.8% | 13.4% | |
| 0.1% | 0.2% | 0.2% | 0.1% | 0.1% | – | 0.0% | 0.4% | 0.0% | 15.5% | 22.4% | 28.7% | |
| 7.0% | -14.1% | 10.2% | 8.2% | 11.6% | – | – | -6.2% | 0.0% | 12.1% | 19.1% | 11.8% | |
| 0.0% | 0.0% | 0.6% | 0.3% | 0.3% | 0.2% | 0.1% | 0.2% | 0.2% | – | – | – | |
| 0.9% | 0.7% | 1.5% | 0.8% | 1.0% | 0.5% | 0.1% | 0.2% | 0.4% | 0.2% | 0.1% | – | |
| 0.9% | 0.7% | 1.5% | 0.8% | – | – | – | – | – | – | – | – | |
| 100.0% | 100.0% | 100.0% | 100.0% | 71.3% | 76.3% | 17.0% | 37.5% | 69.7% | 51.3% | 61.5% | 39.1% | |
| 5.9% | 9.3% | 30.8% | 28.7% | 46.5% | 51.8% | 14.0% | 17.2% | 27.5% | 16.3% | 15.7% | 14.5% | |
| 0.3% | 0.2% | 0.1% | 0.1% | 0.1% | 1.0% | 3.8% | 0.6% | 0.8% | 0.4% | 0.2% | 0.1% | |
| 4.6% | 8.2% | 27.9% | 26.6% | 43.5% | 18.4% | 5.9% | 13.5% | 21.7% | 11.7% | 10.1% | 10.1% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | 17.8% | 1.2% | 17.6% | 36.7% | 30.4% | 42.3% | 23.1% | |
| 92.3% | 89.5% | 65.5% | 68.8% | 28.7% | 23.7% | 83.0% | 62.5% | 30.3% | 48.7% | 38.5% | 60.9% | |
| -109.7% | -139.4% | -431.5% | -364.4% | -631.9% | -430.2% | -156.7% | -350.0% | -788.9% | -471.1% | -264.7% | -101.8% | |
| 39.3% | 40.2% | 89.5% | 63.7% | 90.3% | 54.2% | 18.4% | 34.8% | 70.0% | 45.1% | 27.8% | 15.2% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.